Cravacin Deucravacitinib 6mg Tablets

Cravacin Deucravacitinib 6mg Tablets are an advanced oral medication used for the treatment of moderate-to-severe plaque psoriasis in adults who require systemic therapy. Deucravacitinib belongs to a newer class of targeted therapies known as TYK2 (Tyrosine Kinase 2) inhibitors. It works by selectively blocking specific immune pathways responsible for inflammation, helping to reduce the symptoms associated with chronic autoimmune skin conditions.

Plaque psoriasis is characterised by red, scaly, and itchy skin patches that can significantly affect quality of life. Cravacin 6 mg tablets help control the underlying immune response that triggers excessive skin cell production and inflammation. By targeting TYK2 signalling pathways, the medication helps improve skin clearance, reduce plaque formation, and minimise discomfort associated with psoriasis while maintaining a favourable safety profile compared to broader immunosuppressive treatments.

Cravacin (deucravacitinib) tablets are taken orally as prescribed by a healthcare professional. Regular monitoring and adherence to treatment can help achieve long-term symptom control and improved skin appearance. This innovative therapy offers a convenient treatment option for adults seeking effective management of plaque psoriasis and enhanced overall skin health.

Product Features

• Contains deucravacitinib 6 mg, a selective TYK2 inhibitor
• Used for the treatment of moderate to severe plaque psoriasis
• Helps reduce skin inflammation and plaque formation
• Convenient oral tablet formulation for daily use
• Targets specific immune pathways involved in psoriasis

How It Helps

• Reduces inflammation associated with plaque psoriasis
• Helps improve skin clarity and reduce scaling
• Controls overactive immune responses causing skin lesions
• Supports long-term management of chronic psoriasis symptoms